Rebound Increase in Platelet Aggregation Following withdrawal of DAPT
Research type
Research Study
Full title
Is There a Rebound Increase in Platelet Aggregation Following Withdrawal of Aspirin or Ticagrelor in Patients who have Previously Undergone PCI with Coronary Stenting?
IRAS ID
170133
Contact name
Keith G. Oldroyd
Contact email
Sponsor organisation
NHS
Duration of Study in the UK
0 years, 4 months, 28 days
Research summary
This sub-study will recruit patients already enrolled in the GLOBAL LEADERS Randomised Control Trial. The main GLOBAL LEADERS trial aims to evaluate the best strategy of dual anti-platelet therapy by comparing different combinations of medication in patients receiving angioplasty and stenting. (A stent is a metallic scaffold that is expanded and applied to the blood vessel wall to keep it open after the vessel is opened by expanding a balloon.)
This observational sub-study of GLOBAL LEADERS aims to determine whether degree of platelet aggregation (clot formation) is different when aspirin is withdrawn versus when ticagrelor (or clopidogrel) is withdrawn. The patients recruited will be 'all comers' already participating in GLOBAL LEADERS who have not yet stopped their second blood thinning medication as per the trial protocol. Since the patient's have already been randomly allocated to stop aspirin or ticagrelor the patient's management is not modified in any way by inclusion into this sub-study.
This study will take place at the Golden Jubilee Hospital, Glasgow
The study will last approximately 8 days from the point the patient is recruited. The patient will have blood taken immediately before cessation. This will be repeated at 2,7 and 14 days after cessation and platelet function tests will be performed. (platelet function tests evaluate the degree of platelet aggregation and thus the propensity of the blood to clot)
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
14/WM/1269
Date of REC Opinion
11 Dec 2014
REC opinion
Favourable Opinion